Breast cancer has not previously been considered a highly immunogenic cancer.
Observations of tumour-infiltrating lymphocytes (TILs) in and around neoplastic cells in
tumour samples, and associations with improved pathological complete response and
clinical survival end points have changed our perspective on this. Lymphocytic infiltrates
have long been observed in breast cancer; however, more recently, retrospective analysis of
prospectively collected tissue samples from clinical trials has demonstrated the potential role …